VIVUS (VVUS) Qsymia Continues to See Strong Early Demand
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
VIVUS (VVUS) Qsymia Prescriptions Keep Chugging, Gain 27%+ Last Week
October 22, 2012 10:08 AM EDTVIVUS (Nasdaq: VVUS) is lower Monday amid new data for the fourth-week of its Qsymia roll out showing continued market penetration.
According to data compiled by Cowen & Company, Qsymia had 1,626 new prescriptions for the week ended October 12th, a 27 percent jump from 1,278... More
